Bausch + Lomb (BLCO) is trading higher as investors react to the company’s first-quarter 2026 results and a guidance raise issued on April 29, 2026. The company posted $1.244 billion in Q1 revenue and increased its full-year 2026 outlook for both revenue and adjusted EBITDA excluding acquired IPR&D, signaling stronger-than-expected operating momentum heading into the rest of the year. �citeturn0search0turn1search4

In Q1 2026, total revenue rose 9% year over year (6% constant currency). Segment performance showed broad-based growth: Vision Care revenue was $711 million (+8% reported), Surgical was $228 million (+7% reported), and Pharmaceuticals was $305 million (+14% reported). Operating income improved to $33 million versus an operating loss a year earlier, while the GAAP net loss narrowed to $71 million and adjusted EPS was $0.05. �citeturn0search0

Bausch + Lomb lifted full-year 2026 revenue guidance to $5.420 billion–$5.520 billion (from $5.375 billion–$5.475 billion previously) and raised adjusted EBITDA excluding acquired IPR&D guidance to $1.010 billion–$1.060 billion (from $1.000 billion–$1.050 billion). The update implies management sees continued demand strength and incremental operating leverage after Q1 outperformance, rather than a one-quarter spike. �citeturn0search0turn1search4

Management highlighted growth across key brands and categories, including dry eye, premium intraocular lenses, and daily silicone hydrogel contact lenses. Pharmaceuticals growth was led by MIEBO (+33%) and XIIDRA (+30%), while the company also pointed to operational efficiencies and ongoing launches in the U.S. (including PreserVision AREDS3 and Blink Triple Care Preservative Free) as distribution builds. �citeturn0search0